These inhibitors, including nivolumab (anti PD-1), pembrolizumab (anti PD-1), and atezolizumab (anti PD-L1), have demonstrated superiority over second-line chemotherapy after a failure of platinum-based chemotherapy in NSCLC [2,5,6]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.